Answers are grounded in this paper and cite their sources.
Review demonstrates aging-related drivers in metabolic dysfunction-associated steatotic liver disease, highlighting novel targets across aging populations.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the world's population and has become a leading cause of chronic liver disease. In recent years, an increasing amount of data suggests that MASLD is associated with aging. As the population ages, age-related MASLD will become a major global health problem. Targeting an aging will become a new approach to the treatment of MASLD. This paper reviews the current studies on the role of aging-related factors and therapeutic targets in MASLD, including: Oxidative stress, autophagy, mitochondrial homeostasis, bile acid metabolism homeostasis, and dysbiosis. The aim is to identify effective therapeutic targets for age-related MASLD and its progression.
No takes yet. Share an insight, caveat, or question.
He et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: